{"url_path":"/sec/nrxp/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-017397-index.html","accession_number":"0001437749-26-017397","cik":"0001719406","ticker":"NRXP","issuer_name":"NRX Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-017397-index.html","primary_entity_key":"0001719406","primary_entity_name":"NRX Pharmaceuticals, Inc."},"word_count":49,"has_tables":true,"body_markdown":"**Item 1. Legal Proceedings**\n\n \n\nSee Note 8, Commitments and Contingencies, of the notes to the Company’s unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2026 included elsewhere in this report for further discussion of certain legal proceedings in which we are involved."}